Cidara Therapeutics在ISRV第八届AVG和第三届IMRP 2025会议上公布CD388药物2B期Navigate试验及针对H5N1病毒临床前研究数据

美股速递
Sep 17, 2025

Cidara Therapeutics在ISRV第八届AVG和第三届IMRP 2025会议上展示了其药物CD388在2B期Navigate试验中的数据,以及针对H5N1病毒的临床前研究结果。

该公司在此次重要的国际会议上发表了CD388药物的最新研究进展,包括正在进行的2B期Navigate临床试验的相关数据,同时还公布了该药物在对抗H5N1病毒方面的临床前研究成果。

这些研究数据的公布为Cidara Therapeutics在抗病毒药物开发领域的进展提供了重要参考,特别是在应对流感病毒威胁方面展现出的潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10